Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer - PubMed (original) (raw)
Clinical Trial
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer
Thomas J Vogl et al. Eur Radiol. 2010 Jan.
Abstract
The purpose of this study was to evaluate the efficacy of transarterial chemoembolization (TACE) using different drug combinations in the treatment of breast cancer liver metastases in terms of local tumor control and survival rate. A total of 208 patients (mean age 56.4 years, range 29-81) with unresectable hepatic metastases of breast cancer were repeatedly treated with TACE at 4-week intervals. In total, 1,068 chemoembolizations were performed (mean 5.1 sessions/patient, range 3-25). The chemotherapy protocol consisted of mitomycin-C only (8 mg/m(2); n = 76), mitomycin-C with gemcitabine (n = 111), and gemcitabine only (1,000 mg/m(2); n = 21). Embolization was performed with lipiodol and starch microspheres. Tumor response was evaluated by MRI according to RECIST criteria. Survival rates were calculated using Kaplan-Meier method. For all protocols, local tumor control was partial response 13% (27/208), stable disease 50.5% (105/208), and progressive disease 36.5% (76/208). The 1-, 2-, and 3-year survival rates after TACE were 69, 40, and 33%. Median and mean survival times from the start of TACE were 18.5 and 30.7 months. Treatment with mitomycin-C only showed median and mean survival times of 13.3 and 24 months, with gemcitabine only they were 11 and 22.3 months, and with a combination of mitomycin-C and gemcitabine 24.8 and 35.5 months. TACE is an optional therapy for treatment of liver metastases in breast cancer patients with better results from the combined chemotherapy protocol.
Similar articles
- Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management.
Vogl TJ, Naguib NN, Lehnert T, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Vogl TJ, et al. Gynecol Oncol. 2012 Feb;124(2):225-9. doi: 10.1016/j.ygyno.2011.11.001. Epub 2011 Nov 9. Gynecol Oncol. 2012. PMID: 22079359 - Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Vogl TJ, et al. Radiology. 2009 Jan;250(1):281-9. doi: 10.1148/radiol.2501080295. Radiology. 2009. PMID: 19092099 - Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma.
Vogl TJ, Naguib NN, Nour-Eldin NE, Farshid P, Lehnert T, Gruber-Rouh T, Engels KS. Vogl TJ, et al. Acad Radiol. 2012 Apr;19(4):434-9. doi: 10.1016/j.acra.2011.12.009. Epub 2012 Jan 23. Acad Radiol. 2012. PMID: 22265853 - [Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature].
Wasser K, Giebel F, Fischbach R, Tesch H, Landwehr P. Wasser K, et al. Radiologe. 2005 Jul;45(7):633-43. doi: 10.1007/s00117-004-1061-5. Radiologe. 2005. PMID: 15316615 Review. German. - Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.
Carle X, Gastaud L, Salleron J, Tardy MP, Caujolle JP, Thyss A, Thariat J, Chevallier P. Carle X, et al. Bull Cancer. 2020 Dec;107(12):1274-1283. doi: 10.1016/j.bulcan.2020.09.010. Epub 2020 Nov 9. Bull Cancer. 2020. PMID: 33183739 Review.
Cited by
- The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in breast cancer patients.
Yamaguchi H, Fukumitsu N, Numajiri H, Ogino H, Okimoto T, Ogino T, Suzuki M, Murayama S. Yamaguchi H, et al. J Radiat Res. 2024 Mar 22;65(2):231-237. doi: 10.1093/jrr/rrad106. J Radiat Res. 2024. PMID: 38321606 Free PMC article. - Prediction of small molecule drug-miRNA associations based on GNNs and CNNs.
Niu Z, Gao X, Xia Z, Zhao S, Sun H, Wang H, Liu M, Kong X, Ma C, Zhu H, Gao H, Liu Q, Yang F, Song X, Lu J, Zhou X. Niu Z, et al. Front Genet. 2023 May 30;14:1201934. doi: 10.3389/fgene.2023.1201934. eCollection 2023. Front Genet. 2023. PMID: 37323664 Free PMC article. - Effectiveness of proton beam therapy for liver oligometastatic recurrence in patients with postoperative esophagus cancer.
Yamaguchi H, Kato T, Honda M, Hamada K, Seto I, Tominaga T, Takagawa Y, Takayama K, Suzuki M, Kikuchi Y, Teranishi Y, Murakami M. Yamaguchi H, et al. J Radiat Res. 2023 May 25;64(3):582-589. doi: 10.1093/jrr/rrad009. J Radiat Res. 2023. PMID: 36913708 Free PMC article. - Role of interventional oncology for treatment of liver metastases: evidence based best practice.
Stavrovski T, Pereira P. Stavrovski T, et al. Br J Radiol. 2022 Sep 1;95(1138):20211376. doi: 10.1259/bjr.20211376. Epub 2022 Aug 17. Br J Radiol. 2022. PMID: 35976260 Free PMC article. Review. - Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review.
Aoki S, Yamashita H, Abe O, Nakagawa K. Aoki S, et al. Transl Cancer Res. 2020 Aug;9(8):5087-5095. doi: 10.21037/tcr-20-1833. Transl Cancer Res. 2020. PMID: 35117874 Free PMC article. Review.
References
- Radiology. 2001 Jul;220(1):145-9 - PubMed
- Eur J Surg Oncol. 2000 Mar;26(2):155-9 - PubMed
- AJR Am J Roentgenol. 2007 May;188(5):1201-7 - PubMed
- Oncologist. 2003;8(5):425-37 - PubMed
- Anticancer Res. 1998 May-Jun;18(3C):2231-3 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous